Drug Trial Radar · NCT03626688
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
Last checked: Nov 19, 2026Latest source record: Jun 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
687
Actual
Start
Jan 24, 2019
Primary completion
Dec 31, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- United TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Aug 13, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.
Conditions
- PAH
- Pulmonary Hypertension
- Pulmonary Arterial Hypertension
- Hypertension
- Connective Tissue Diseases
- Familial Primary Pulmonary Hypertension
- Vascular Diseases
- Cardiovascular Diseases
- Hypertension, Pulmonary
- Lung Diseases
- Respiratory Tract Disease
Interventions
RalinepagDrug
Active
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time from randomization to the first adjudicated protocol-defined clinical worsening eventTime frame: The study duration was event-based. This parameter was assessed from randomization until the conclusion of the study, up to 3 years
Locations
209 sites in 33 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
St. Joseph's Hospital and Medical Center
Phoenix, Arizona
University of Arizona
Tucson, Arizona
UCSD Health Sciences
La Jolla, California
Loma Linda University Medical Center
Loma Linda, California
Ronald Reagan UCLA Medical Center
Los Angeles, California
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California
Keck Hospital of USC
Los Angeles, California
Cedars-Sinai Medical Center
Los Angeles, California
VA Greater Los Angeles Healthcare System
Los Angeles, California
University of California, Irvine
Orange, California
University of California Davis Medical Center
Sacramento, California
SBPA Research LLC
Santa Barbara, California
Stanford Healthcare
Stanford, California
LA Biomedical Research Institute Harbor-UCLA Medical Center
Torrance, California
University of Colorado Hospital
Aurora, Colorado
National Jewish Health
Denver, Colorado
University of Florida
Gainesville, Florida
University of Miami
Miami, Florida
Central Florida Pulmonary Group
Orlando, Florida
Cleveland Clinic Florida
Weston, Florida
Emory University Hospital
Atlanta, Georgia
Piedmont Healthcare Pulmonary and Critical Care Research
Austell, Georgia
University of Chicago Medical Center
Chicago, Illinois
Ascension Alexian Brothers
Elk Grove Village, Illinois
Indiana University School of Medicine
Indianapolis, Indiana
Community Health Network Cancer Center North
Indianapolis, Indiana
St. Vincent Medical Group, Inc.
Indianapolis, Indiana
University of Iowa Hospitals and Clinics
Iowa City, Iowa
Kentuckiana Pulmonary Research Center
Louisville, Kentucky
Ochsner Medical Center
New Orleans, Louisiana
Chest Medicine Associates
South Portland, Maine
University of Maryland Medical Center
Baltimore, Maryland
Tufts Medical Center
Boston, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts
Boston University Medical Center
Boston, Massachusetts
Spectrum Health Medical Group
Grand Rapids, Michigan
Washington University School of Medicine
St Louis, Missouri
Nebraska Medical Center
Omaha, Nebraska
University of New Mexico
Albuquerque, New Mexico
Showing 40 of 209 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.